目的 探討瓜蔞皮注射液聯(lián)合磷酸肌酸治療冠心病穩(wěn)定型心絞痛的臨床療效。方法 選取2020年1月—2021年4月在鄭州頤和醫(yī)院診治的144例冠心病穩(wěn)定型心絞痛患者，隨機分為對照組（72例）和治療組（72例）。對照組患者靜脈滴注注射用磷酸肌酸鈉，1 g加入100 mL生理鹽水，1次/d。治療組在對照組的基礎(chǔ)上肌內(nèi)注射瓜蔞皮注射液，4 mL/次，1次/d。兩組患者均治療7 d。觀察兩組患者臨床療效，比較治療前后兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時間，24 h動態(tài)心電圖變化，氧化應(yīng)激指標(biāo)總抗氧化能力（T-Aoc）、谷胱甘肽過氧化物酶（GSH-Px）和糖基化終末產(chǎn)物（AGEs）水平及血管內(nèi)皮功能指標(biāo)一氧化氮（NO）、血管內(nèi)皮生長因子（VEGF）、內(nèi)皮素-1（ET-1）和可溶性血栓調(diào)節(jié)蛋白（sTM）水平。結(jié)果 治療后，對照組總有效率80.56%，治療組總有效率93.06%，兩組總有效率比較差異具有統(tǒng)計學(xué)意義（P<0.05）。兩組患者心絞痛發(fā)作次數(shù)、心絞痛每次持續(xù)時間較治療前下降（P<0.05），且治療組下降幅度更明顯（P<0.05）。治療后，兩組患者缺血發(fā)作次數(shù)、缺血最長持續(xù)時間、缺血總時間顯著降低（P<0.05），且治療組缺血發(fā)作次數(shù)、缺血最長持續(xù)時間、缺血總時間顯著低于對照組（P<0.05）。治療后，兩組患者T-Aoc、GSH-Px水平均顯著升高，AGEs水平顯著降低（P<0.05），且治療組上述指標(biāo)改善更顯著（P<0.05）。治療后，兩組患者NO、VEGF水平顯著升高，ET-1、sTM水平顯著降低，且治療組上述指標(biāo)改善更顯著（P<0.05）。結(jié)論 瓜蔞皮注射液聯(lián)合磷酸肌酸可有效改善冠心病穩(wěn)定型心絞痛患者臨床癥狀，改善冠脈循環(huán)，抑制氧化應(yīng)激反應(yīng)，減輕血管內(nèi)皮損傷，具有良好的臨床療效，安全性較高。

Objective To investigate the clinical efficacy of Gualoupi Injection combined with phosphocreatine in treatment of stable angina pectoris of coronary heart disease. Methods Patients (144 cases) with stable angina pectoris of coronary heart disease in Zhengzhou Yihe Hospital from January 2020 to April 2021 were randomly divided into control (72 cases) and treatment (72 cases) group. Patients in the control group were iv administered with Creatine Phosphate Sodium for injection, 1 g added into 100 mL normal saline, once daily. Patients in the treatment group were intramuscular injection administered with Gualoupi Injection on the basis of the control group, 4 mL/time, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, the attack times and duration of angina pectoris, 24 h ambulatory ECG changes, oxidative stress response indexes T-Aoc, GSH-Px and AGEs, and vascular endothelial function indexes NO, VEGF, ET-1 and sTM in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.56%, while the treatment group was 93.06%, respectively, and there were differences between two groups (P < 0.05). After treatment, the frequency of angina attacks and the duration of angina pectoris in two groups were significantly decreased compared with those before treatment (P < 0.05), and the decrease in the treatment group was more obvious (P < 0.05). After treatment, the number of ischemic attacks, the longest duration of ischemia and the total duration of ischemia in the two groups were significantly decreased (P < 0.05), and the number of ischemic attacks, the longest duration of ischemia and the total duration of ischemia in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, T-Aoc and GSH-Px in two groups were significantly increased, while AGEs were significantly decreased (P < 0.05), the improvement degree in treatment group was significantly higher than control group (P < 0.05). The levels of NO and VEGF in two groups were significantly increased, the levels of ET-1 and sTM were significantly decreased (P < 0.05), however, the improvement of the above indicators in the treatment group was more obvious (P < 0.05). Conclusion Gualoupi Injection combined with phosphocreatine can effectively improve the clinical symptoms of patients with stable angina pectoris of coronary heart disease, improve coronary circulation, inhibit oxidative stress response and reduce vascular endothelial injury. It has good clinical efficacy and high safety.

R972